Testing a new immune-boosting medication combined with standard immunotherapy for advanced lung cancer

Plain-English translation of NCT07027514 on ClinicalTrials.gov ↗ · Source last updated November 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This clinical trial is testing , a new medication designed to boost your immune system's ability to fight cancer, when used together with standard immunotherapy drugs. Researchers want to see if this combination is safe and effective for people with advanced non-small cell lung cancer. There are two groups in the study: one for people whose cancer has progressed despite previous treatment, and another for people who haven't had prior immunotherapy.

Standard immunotherapy drugs help some patients, but many people's cancers stop responding to them over time or don't respond at all. This trial is exploring whether adding the new medication to enhance the immune system's response could help more patients benefit from treatment.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or metastatic non-small cell lung cancer
you are in overall good health with normal thyroid function and good physical performance status
you have measurable disease that can be seen on imaging scans
you have a life expectancy of at least 12 weeks
you are willing to have a fresh tumor biopsy collected during the study

You likely don't qualify if…

you have mutations in your EGFR or ALK genes
you have active autoimmune disease or need chronic steroid medications
you have untreated brain metastases or certain serious heart conditions
you have uncontrolled bleeding disorders or active hepatitis B or C
you are pregnant, breastfeeding, or cannot use reliable birth control during the study

What participation looks like

If you join this trial, you will receive the new medication combined with an immunotherapy drug over about one year (up to 8 treatment cycles). You'll have regular visits to your clinic for blood tests, imaging scans, and heart monitoring with an electrocardiogram. You'll also need to provide a fresh tumor biopsy sample. The study team will carefully monitor you for side effects and how well the treatment is working.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(5 sites)

United States

Community Health Network, Indianapolis, Indiana

Barbara Ann Karmanos Cancer Hospital, Detroit, Michigan

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Icahn School of Medicine at Mount Sinai, New York, New York

FirstHealth of the Carolinas, Pinehurst, North Carolina